Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study

NCT06685835 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT06685835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06685835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study
Lead sponsor
Insmed Incorporated
Phase
Phase 2
Overall status
Terminated
Start date
December 16, 2024
Completion date
June 8, 2026
Enrollment
214 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa